New Drug for Hepatitis B

Slows virus that causes deadly liver disease

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

WEDNESDAY, March 30, 2005 (HealthDay News) -- The U.S. Food and Drug Administration has approved the newBristol-Meyers Squibb drug Baraclude (entecavir) to treat chronichepatitis B in adults, the agency announced Wednesday.

About 1.25 million Americans are infected with the hepatitis B virus(HBV), which attacks the liver and can cause lifelong infection,cirrhosis, liver cancer, liver failure, and death, the FDA said.Baraclude slows the virus' effects by interfering with its ability toreproduce.

In clinical trials, patients showed significant improvement comparedwith those who took an older HBV therapy, lamivudine, the agency said.

Side effects of the new drug included headache, abdominal pain,diarrhea, fatigue and dizziness. The company said the medication couldbe available as soon as early April.

To learn more about hepatitis B, visit the U.S. Centers for Disease Control and Prevention.

--

Last Updated: